| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.005 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.089 | 0.005 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.098 | 0.006 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.008 |